01 / 20

Pulmonary Embolism
& Anticoagulation Follow-Up

How to diagnose, treat, and follow up clots that travel to the lungs, and how to choose the right blood thinner and duration.

USMLE Step 3

What Is a Pulmonary Embolism?

A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs. Most often it begins as a deep vein thrombosis (DVT): a clot that forms in the deep veins of the legs and then breaks loose and travels through the heart to the lungs.

From Leg Vein to Lung Artery

Leg vein DVT forms travels Right heart Lung artery PE lodges here

How PE Presents

Sudden Dyspnea
Acute shortness of breath, the most common symptom.
Pleuritic Pain
Sharp chest pain that worsens with breathing.
Tachycardia
Fast heart rate, sometimes with low oxygen saturation.

The Diagnostic Pathway

Start with the Wells score to estimate pretest probability. The strategy splits on probability:

1
Low probability: order a D-dimer. If \( \text{D-dimer} < 500 \,\text{ng/mL} \), PE is effectively ruled out.
2
Elevated D-dimer or high probability: proceed to CT pulmonary angiography (CTPA), the confirmatory test.
3
Renal failure or contrast allergy: use a V/Q scan instead of CTPA.

Wells Score Decision Tree

Suspect PE Wells score Low High Check D-dimer negative = ruled out Go to CTPA if elevated CTPA confirms PE begin treatment

Core Rule: Anticoagulate

Once PE is confirmed (or strongly suspected with stable vitals), the foundation of treatment is anticoagulation: blood thinners that stop new clot formation and let the body break down existing clot.

DOAC vs Warfarin

DOAC Warfarin
MonitoringNone routineINR checks
TargetFixed dose\( \text{INR} \, 2{-}3 \)
OnsetRapidNeeds bridge
PregnancyAvoidAvoid
Severe renal/APSAvoidPreferred

How to Choose Duration

1
Provoked (reversible cause): surgery, trauma, immobilization → 3 months of anticoagulation, then stop.
2
Unprovoked (no clear cause): consider extended/indefinite therapy if bleeding risk is acceptable.
3
Active cancer: anticoagulate as long as cancer is active, usually with a DOAC or LMWH.
4
Recurrent VTE: indefinite anticoagulation is generally indicated.

Anticoagulation Follow-Up

Bleeding Check
Assess for bruising, GI bleeding, and falls at each visit.
Renal Function
Recheck \( \text{CrCl} \) for DOACs, as dosing depends on it.
Reassess Duration
At 3 months, decide stop vs extended therapy.

Example 1: Provoked PE

A 55-year-old man develops a confirmed PE 2 weeks after knee surgery. He is hemodynamically stable, with normal renal function and no bleeding history.

Example 2: Unprovoked PE

A 48-year-old woman has a first unprovoked PE, no surgery, no immobility, no cancer. Stable vitals, low bleeding risk on assessment.

Example 3: Massive PE

A 62-year-old woman with a large PE is hypotensive with \( \text{SBP} = 82 \,\text{mmHg} \) and signs of right heart strain on echo.

Common Mistakes

✕ D-dimer in high-risk
Skip D-dimer when probability is high; go straight to CTPA.
✕ DOAC in APS
Use warfarin, not DOACs, for antiphospholipid syndrome.
✕ Stopping too early
Unprovoked VTE often needs extended therapy, not just 3 months.
✕ tPA in stable PE
Thrombolysis is for shock, not for routine stable PE.

Duration Summary

Scenario Duration Agent
Provoked, reversible3 monthsDOAC
UnprovokedExtended / indefiniteDOAC
Active cancerWhile cancer activeDOAC / LMWH
Recurrent VTEIndefiniteDOAC / warfarin
PregnancyPer pregnancyLMWH

Question 1 of 5

A patient has a high clinical probability of PE based on Wells score. What is the best next step?

Question 2 of 5

A stable patient with PE provoked by recent hip surgery and normal renal function should receive anticoagulation for how long?

Question 3 of 5

A PE patient with confirmed antiphospholipid syndrome needs anticoagulation. Which agent is preferred?

Question 4 of 5

A PE patient is hypotensive with \( \text{SBP} = 78 \,\text{mmHg} \) and right heart strain. Besides anticoagulation, what should be considered?

Question 5 of 5

A patient on a DOAC for PE returns for follow-up. Which lab is most important to monitor for safe dosing?